Continuum of dose-dependent effects
Barbiturates exhibit a pronounced dose-dependent pharmacological effect. They cause a non-selective depressant effect on brain functions that develops sequentially:
- Low doses provide a sedative (calming) effect.
- Moderate doses produce a pronounced hypnotic effect, which manifests as easier sleep onset and an increase in total sleep duration.
- High doses lead to anesthesia (general anesthesia). This is why ultra-short-acting drugs (e.g., thiopental sodium) are used clinically for non-inhalational general anesthesia.
In addition, drugs of this group possess anticonvulsant activity.
Molecular mechanism of action
The site of action of barbiturates is specific barbiturate receptors within the macromolecular "GABA-A receptor-chloride channel" complex. It is important to note that their binding sites are spatially distinct from benzodiazepine receptors.
The cellular-level effect involves several mechanisms:
- Potentiation of GABA effects: The drugs increase receptor sensitivity to gamma-aminobutyric acid. The main feature of the group is that they specifically increase the duration of chloride channel opening.
- Membrane hyperpolarization: A massive influx of chloride ions (Cl-) into the neuron occurs. The membrane hyperpolarizes, leading to a powerful enhancement of inhibitory processes.
- Direct GABA-mimetic action: At high anesthetic doses (as with thiopental sodium), barbiturates can independently open chloride channels even without the involvement of the GABA neurotransmitter.
- Antagonism to excitatory neurotransmitters: The substances additionally inhibit the stimulatory action of glutamate.
Effect on sleep architecture and consequences of use
Hypnotic drugs with a narcotic-like action drastically interfere with normal sleep architecture. They cause a significant shortening of the rapid eye movement (REM) sleep phase.
Abrupt discontinuation leads to a withdrawal syndrome known as the "rebound phenomenon." The REM sleep phase is compensatorily prolonged, which clinically manifests as exhausting nightmares.
The safety profile of the group is extremely unfavorable due to the narrow therapeutic index — there is a high risk of toxic complications, the chief of which is life-threatening depression of the respiratory center.
Additional therapy-related issues:
- Hangover effect: Symptoms (lethargy, drowsiness, impaired attention, coordination, and psychomotor reactions) persist throughout the following day even after a single dose.
- Material accumulation: Drugs easily accumulate in the body upon repeated administration, which only enhances the depression of higher nervous activity and the hangover effect.
Pharmacokinetics, tolerance, and withdrawal syndrome
Barbiturates (especially phenobarbital) are active inducers of hepatic microsomal enzymes. This leads to accelerated metabolism of other co-administered drugs (reducing their therapeutic efficacy) and to auto-induction — the accelerated breakdown of the barbiturate itself.
Due to enzyme induction, tolerance (habituation) develops extremely rapidly — the need for a dose increase may arise within just 2 weeks of regular administration.
Prolonged use (for 1–3 months) in sufficient doses guarantees severe physical and psychological drug dependence. Withdrawal syndrome upon discontinuation is severe and accompanied by:
- Psychoneurological symptoms (anxiety, overwhelming fear, visual disturbances, convulsions).
- Autonomic and somatic disorders (vomiting, orthostatic hypotension).
- In severe cases of withdrawal, a fatal outcome is possible.
Due to the serious side effects described, the use of barbiturates in clinical practice has been sharply reduced, and most drugs have been excluded from the State Register of Pharmaceuticals. As an exception, long-acting drugs continue to be used occasionally as hypnotics.
To memorize the continuum of barbiturate effects depending on the dose: Sedation (low) → Sleep (moderate) → Anesthesia (high).
Class and exam questions
Why are barbiturates hardly used as hypnotics nowadays?
Due to the narrow therapeutic window, high risk of fatal depression of the respiratory center, pronounced hangover effect, and the ability to cause severe physical dependence.
What is the specific feature of the action of barbiturates on the GABA-A receptor?
Unlike other groups, they bind to specific barbiturate receptors and specifically increase the time (duration) of chloride channel opening.
How do these drugs affect the liver and the metabolism of other drugs?
They induce hepatic microsomal enzymes, which significantly accelerates the metabolism of both other administered drugs (reducing their efficacy) and the barbiturates themselves (development of tolerance).
What is the "rebound phenomenon" when taking barbiturates?
This is a severe syndrome upon abrupt drug discontinuation, manifested by a compensatory prolongation of the REM sleep phase and accompanied by pronounced nightmares.
What else to study on this topic
- Clinical use of thiopental sodium in anesthesiology
- Anticonvulsant action of barbituric acid derivatives
- Features of hepatic enzyme auto-induction using phenobarbital as an example
- Management tactics for patients with severe withdrawal syndrome following barbiturate use
- Comparison of the mechanism of action of barbiturates and benzodiazepines
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Barbiturates (Hypnotics)" and 5,304 more subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Agents Used in Psychiatry and Neurology"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.